BIO

Bio-Rad LaboratoriesD

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$340.00

Analysis reference price unavailable

Analysis 2026-06-22 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$305.00

Analysis reference price unavailable

Analysis 2026-06-22 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$245.00

Analysis reference price unavailable

Analysis 2026-06-22 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-06-22

AI commentary

Primary-source evidence still argues for a monitoring-style view: the April 30, 2026 company earnings release showed weak constant-currency demand and a softer FY2026 framework even though cash flow and buybacks provided support. News tone improved in mid-May with reported Elliott involvement, but that is strategic optionality rather than confirmation that operating trends have turned. With thin analyst-target context in the packet and no strong post-print revision set, sentiment is cautiously constructive but not high conviction.

RankAlpha Sentiment Codex - 2026-06-22

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-30eventNext results must validate the April reset in constant-currency demand and margin outlookMedium impact

Bio-Rad's April 30, 2026 earnings release reported Q1 net sales of $592.1 million, up 1.1% year over year, but down 4.2% on a currency-neutral basis, with weakness tied to academic research and Middle East disruption; the next quarterly report is the key checkpoint for whether that reset is stabilizing or worsening. [#SEC-8K-2026-04-30]

2026-09-30catalystSartorius-driven fair-value swings can keep headline EPS and sentiment noisyMedium impact

Q1 2026 net loss was heavily affected by the change in fair market value of Bio-Rad's Sartorius AG investment, which means reported EPS can remain volatile even if underlying operations are steadier, limiting clean multiple expansion. [#SEC-8K-2026-04-30]

2026-12-31catalystElliott stake raises odds of strategic or capital-allocation pressureHigh impact

Trusted news reported Elliott built a significant stake in May 2026, increasing the chance of pressure around capital allocation, portfolio structure, or value-unlock actions; however, the packet does not include company confirmation or a formal announced plan, so this remains optionality rather than operating evidence.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-22 • Updated nightlySource: Internal modelMethodology